AI heart patch could slash stroke risk in rural seniors
NCT ID NCT06842147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a 7-day AI-enhanced single-lead ECG patch against routine 12-lead ECGs to detect new atrial fibrillation in 15,360 adults aged 60+ in rural China. The goal is to see if longer, smarter monitoring catches more cases and reduces deaths, strokes, and heart failure hospitalizations over three years. Participants wear the patch for a week; no drugs or procedures are tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 15,360 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Age 60 years or older No previous history of atrial fibrillation (AF) Willing to participate in random assignment and follow-up Exclusion Criteria: Patients with a pacemaker or implanted cardioverter-defibrillator (ICD) Patients with cognitive impairment or unable to provide informed consent Patients with an estimated life expectancy of less than one year (e.g., advanced cancer or end-stage renal disease) Patients deemed unsuitable for the study by the investigator Patients who refuse to participate
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Anzhen Hospital
RECRUITINGZhejiang, Quzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- Zapping the ear: a new way to stop Post-Surgery heart rhythm problems?
- Can a new mapping and ablation system fix recurring atrial fibrillation?
- Can shedding pounds stop atrial fibrillation in its tracks?
- Pacemaker algorithm tuned to Heart's pumping may beat standard rate response